Vertex Pharmaceuticals
Prix: 444.93Entreprise et modèle économique
Vertex Pharmaceuticals is a biotechnology company focused on developing and commercializing innovative therapies for serious diseases, primarily cystic fibrosis. Its core products include Kalydeco, Orkambi, Symdeko, and Trikafta, which target the underlying causes of cystic fibrosis. The company generates revenue mainly from product sales and has a strong pipeline of potential therapies in various stages of development.
Profil d’investissement
The investment profile of Vertex Pharmaceuticals is more aligned with growth investors, given its focus on innovation and potential for future revenue expansion through new therapies. The absence of dividends suggests a reinvestment strategy aimed at long-term growth. The stock may appeal to those with a medium to long-term investment horizon, while its moderate volatility indicates a need for a basic level of market experience.
Métriques fondamentales (expérimental)
- BPA (TTM) — bénéfice par action des 12 derniers mois, $
- 17.01 OK
- Chiffre d’affaires QoQ — croissance trimestrielle du chiffre d’affaires
- -7.4% ↓
- Surprise BPA
- 5.4% meilleur que prévu
- Volatilité 20 j
- 1.6% stable
Suivre dans le portefeuille
Graphique des prix
| Date | Avant | Après | Raison |
|---|---|---|---|
| 2026-06-11 05:28 | Conserver | Vendre | Weak fundamentals and negative momentum raise concerns. |
| 2026-05-16 02:35 | Acheter | Conserver | Weak fundamentals and negative momentum raise concerns. |
| 2026-05-14 02:35 | Vendre | Acheter | Mixed performance; watch for recovery signs. |
| Date | Analyste | Action | Objectif | Prix alors |
|---|---|---|---|---|
| 2026-05-27 05:02 | Truist Financial | Mettre à jour | — → 542 | 435.93 |
| 2026-05-06 09:48 | Barclays | Objectif relevé | 607 → 615 | 424.36 |
| 2026-05-05 12:24 | Morgan Stanley | Objectif relevé | 612 → 616 | 417.72 |
Rien pour le moment